Erytech Pharma S.A. (ERYP)
| Market Cap | 163.77M |
| Revenue (ttm) | 4.93M |
| Net Income (ttm) | -78.92M |
| Shares Out | 27.73M |
| EPS (ttm) | -3.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,315 |
| Open | 6.07 |
| Previous Close | 6.05 |
| Day's Range | 5.88 - 6.05 |
| 52-Week Range | 4.10 - 13.00 |
| Beta | 1.92 |
| Analysts | Strong Buy |
| Price Target | 17.76 (+202.0%) |
| Est. Earnings Date | n/a |
About ERYP
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-l...
Financial Performance
In 2020, Erytech Pharma's revenue was 3.72 million, a decrease of -29.62% compared to the previous year's 5.28 million. Losses were -73.30 million, 17.0% more than in 2019.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 3 analysts, the average rating for Erytech Pharma stock is "Strong Buy." The 12-month stock price forecast is 17.76, which is an increase of 202.05% from the latest price.
News
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 20 2 1
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update
ERYTECH t o Host on September 21, 2021 Second Quarter 2021 conference call and Business Update
ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Cambridge, MA (U.S.) and Lyon (France), September 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeu...
ERYTECH to Participate in the Citi 16th Annual BioPharma Conference
ERYTECH to Participate in the Citi 16 th Annual BioPharma Conference
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
ERYP Stock: The Huge FDA News That Has Little-Known Erytech Skyrocketing
ERYP stock is seeing a surge in value this morning, as it lands FDA fast track designation for its eryaspase treatment for a second time. The post ERYP Stock: The Huge FDA News That Has Little-Known Ery...
Why Erytech Pharma's Stock Is Surging Higher Today
Erytech Pharma SA (NASDAQ: ERYP) is surging higher Friday morning after the company announced its eryaspase was granted U.S. FDA Fast Track designation. The Fast Track designation is for the treatment o...
Why Erytech Pharma Shares Are Soaring Today
Erytech Pharma SA (NASDAQ: ERYP) is surging higher in after hours trading after the company announced its eryaspase was granted U.S. FDA Fast Track designation. The Fast Track designation is for the tre...
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
ERYTECH Granted U.S. FDA Fast Track Designation for E ryaspase in Hypersensitive ALL
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference
ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients
ERYTECH Confirms Plans To Submit BLA for E ryaspase in H ypersensitive ALL Patients
Report - Erytech's Combined Shareholders' Meeting on June 25, 2021
REPORT - ERYTECH'S COMBINED SHAREHOLDERS' MEETING ON JUNE 25, 2021
ERYTECH to Participate in Upcoming Virtual Investor Conferences in June
ERYTECH to Participate in Upcoming Virtual Investor Conferences in June
Erytech's Combined Shareholders' Meeting on June 25, 2021
ERYTECH'S COMBINED SHAREHOLDERS' MEE TING
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 20 2 1
ERYTECH Announces $30.0 Million Registered Direct Offering
ERYTECH Announces $ 30.0 Million Registered Direct Offering
ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call
ERYTECH Reports Cash Balance at End of Q1 202 1 and Announces the Details of its 2021 Q1 conference call
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pan...
ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer
ERYTECH to Participate in Upcoming Virtual Investor Conferences in April
ERYTECH to Participate in Upcoming Virtual Investor Conferences in April
ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?
ERYTECH Pharma S.A. (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon
ERYTECH to Present at the 2021 BIO CEO & Investor Conference
ERYTECH to Present at the 2021 BIO CEO & Investor Conference
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancrea...
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer